DongKoo Bio & Pharma Statistics

Total Valuation

DongKoo Bio & Pharma has a market cap or net worth of KRW 138.15 billion. The enterprise value is 180.02 billion.

Market Cap	138.15B
Enterprise Value	180.02B

Important Dates

The next estimated earnings date is Wednesday, March 19, 2025.

Earnings Date	Mar 19, 2025
Ex-Dividend Date	Dec 27, 2023

Share Statistics

DongKoo Bio & Pharma has 27.30 million shares outstanding. The number of shares has decreased by -0.73% in one year.

Current Share Class	n/a
Shares Outstanding	27.30M
Shares Change (YoY)	-0.73%
Shares Change (QoQ)	-0.40%
Owned by Insiders (%)	43.85%
Owned by Institutions (%)	0.68%
Float	15.22M

Valuation Ratios

The trailing PE ratio is 9.06.

PE Ratio	9.06
Forward PE	n/a
PS Ratio	0.55
PB Ratio	1.20
P/TBV Ratio	1.37
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 8.37, with an EV/FCF ratio of -25.16.

EV / Earnings	11.74
EV / Sales	0.71
EV / EBITDA	8.37
EV / EBIT	12.15
EV / FCF	-25.16

Financial Position

The company has a current ratio of 0.99, with a Debt / Equity ratio of 0.66.

Current Ratio	0.99
Quick Ratio	0.54
Debt / Equity	0.66
Debt / EBITDA	3.04
Debt / FCF	-10.54
Interest Coverage	7.25

Financial Efficiency

Return on equity (ROE) is 13.85% and return on invested capital (ROIC) is 6.78%.

Return on Equity (ROE)	13.85%
Return on Assets (ROA)	5.40%
Return on Capital (ROIC)	6.78%
Revenue Per Employee	665.91M
Profits Per Employee	40.25M
Employee Count	381
Asset Turnover	1.21
Inventory Turnover	2.40

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -12.00% in the last 52 weeks. The beta is 0.70, so DongKoo Bio & Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.70
52-Week Price Change	-12.00%
50-Day Moving Average	4,992.80
200-Day Moving Average	6,089.80
Relative Strength Index (RSI)	47.64
Average Volume (20 Days)	213,132

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, DongKoo Bio & Pharma had revenue of KRW 253.71 billion and earned 15.34 billion in profits. Earnings per share was 558.81.

Revenue	253.71B
Gross Profit	155.20B
Operating Income	18.14B
Pretax Income	19.69B
Net Income	15.34B
EBITDA	24.82B
EBIT	18.14B
Earnings Per Share (EPS)	558.81

Full Income Statement

Balance Sheet

The company has 33.66 billion in cash and 75.39 billion in debt, giving a net cash position of -41.74 billion or -1,528.77 per share.

Cash & Cash Equivalents	33.66B
Total Debt	75.39B
Net Cash	-41.74B
Net Cash Per Share	-1,528.77
Equity (Book Value)	114.62B
Book Value Per Share	4,222.02
Working Capital	-1.46B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 18.98 billion and capital expenditures -26.13 billion, giving a free cash flow of -7.16 billion.

Operating Cash Flow	18.98B
Capital Expenditures	-26.13B
Free Cash Flow	-7.16B
FCF Per Share	-262.12

Full Cash Flow Statement

Margins

Gross margin is 61.17%, with operating and profit margins of 7.15% and 6.04%.

Gross Margin	61.17%
Operating Margin	7.15%
Pretax Margin	7.76%
Profit Margin	6.04%
EBITDA Margin	9.78%
EBIT Margin	7.15%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 120.00, which amounts to a dividend yield of 2.34%.

Dividend Per Share	120.00
Dividend Yield	2.34%
Dividend Growth (YoY)	9.09%
Years of Dividend Growth	3
Payout Ratio	21.60%
Buyback Yield	0.73%
Shareholder Yield	3.07%
Earnings Yield	11.04%
FCF Yield	-5.18%

Dividend Details

Stock Splits

The last stock split was on March 2, 2021. It was a forward split with a ratio of 3.

Last Split Date	Mar 2, 2021
Split Type	Forward
Split Ratio	3

Scores

DongKoo Bio & Pharma has an Altman Z-Score of 2.58. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.58
Piotroski F-Score	n/a